

SCIENTIFIC REPORTS



OPEN

Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIIb/IIIa expression

Gyrid Nygaard^{1,2}, Lars Herfindal³, Kathrine S. Asrud¹, Ronja Bjørnstad^{3,4}, Reidun K. Kopperud¹, Eystein Oveland⁵, Frode S. Berven^{1,2}, Lene Myhren¹, Erling A. Hoivik⁵, Turid Helen Felli Lunde⁶, Marit Bakke¹, Stein O. Døskeland¹ & Frode Selheim^{1,2}

Epac1 (Exchange protein directly activated by cAMP 1) limits fluid loss from the circulation by tightening the endothelial barrier. We show here that Epac1^{-/-} mice, but not Epac2^{-/-} mice, have prolonged bleeding time, suggesting that Epac1 may limit fluid loss also by restraining bleeding. The Epac1^{-/-} mice had deficient *in vitro* secondary hemostasis. Quantitative comprehensive proteomics analysis revealed that Epac1^{-/-} mouse platelets (thrombocytes) had unbalanced expression of key components of the glycoprotein Ib-IX-V (GPIb-IX-V) complex, with decrease of GPIIb/IIIa and no change of GPIIb/IIIa. This complex is critical for platelet adhesion under arterial shear conditions. Furthermore, Epac1^{-/-} mice have reduced levels of plasma coagulation factors and fibrinogen, increased size of circulating platelets, increased megakaryocytes (the GPIIb/IIIa level was decreased also in Epac1^{-/-} bone marrow) and higher abundance of reticulated platelets. Viscoelastic measurement of clotting function revealed Epac1^{-/-} mice with a dysfunction in the clotting process, which corresponds to reduced plasma levels of coagulation factors like factor XIII and fibrinogen. We propose that the observed platelet phenotype is due to deficient Epac1 activity during megakaryopoiesis and thrombopoiesis, and that the defects in blood clotting for Epac1^{-/-} is connected to secondary hemostasis.

Damage to blood vessel walls initiates a series of responses to limit blood loss. At the sites of vascular injury extracellular matrix (ECM) proteins become exposed to blood and react with specific platelet receptors to induce a multistep platelet adhesion process¹⁻⁴. At the shear rates in small arteries and microvasculature, the adhesion depends crucially on the GPIb-IX-V platelet receptor's interaction with ECM-bound von Willebrand factor (vWF)². This interaction has a rapid on-off-rate causing platelets to roll along the damaged vessel wall, effectively slowing down the platelet flow rate. This facilitates firm adhesion by allowing time for the GPVI, α2β1, α5β1 and α6β1 receptors to bind effectively to their ligands¹. The integrin receptor αIIbβ3 mediates platelet-platelet interactions by binding to vWF, fibrinogen, fibrin and/or fibronectin³. Hence, platelets aggregate and form a primary hemostatic plug to prevent blood loss into the extravascular space. Conditions with qualitative or quantitative defects in vWF, GPIb-IX-V or αIIbβ3 may cause the bleeding disorders von Willebrand's disease, Bernard-Soulier syndrome (BBS), and Glanzmann's thrombasthenia, respectively^{3,4}.

The exchange proteins directly activated by cAMP (Epacs) belong to the family of specific guanine nucleotide exchange factors (GEFs) for Ras-like small GTPases. The two Epac isoforms, Epac1 and Epac2, act as sensors for the intracellular levels of the second messenger cAMP. Upon binding of cAMP they become capable of changing downstream targets Rap1 and Rap2 from the inactive GDP to the active GTP-form. The Epac proteins are involved in the regulation of several processes, such as cellular differentiation, secretion, adhesion, and proliferation, and our group has recently shown that Epac1 limits fluid loss from the circulation by tightening the endothelial barrier^{5,6}. Before the discovery of Epac in 1998, many of the processes controlled by Epac were attributed to the cAMP-dependent protein kinase A (PKA)⁷. Interestingly, crosstalk between Epac and PKA signaling has been reported; in some instances they operate in concert while in others they exert opposite effects⁸. To add further

¹Department of Biomedicine, University of Bergen, Bergen, Norway. ²The Proteomics Unit at the University of Bergen, Bergen, Norway. ³Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway. ⁴Hospital Pharmacies Enterprise, Western Norway, Bergen, Norway. ⁵Department of Clinical Science, University of Bergen, Bergen, Norway. ⁶Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway. Correspondence and requests for materials should be addressed to F.S. (email: Frode.Selheim@uib.no)

complication, Epac1 and PKA have similar affinity for cAMP *in vitro* and can thus respond to similar concentrations of intracellular cAMP⁹.

PKA-mediated cAMP signaling in platelets has been extensively studied and has an inhibitory effect on platelet activation (reviewed in¹⁰). Although a single article reported trace amounts of Epac1 mRNA and protein in platelets¹¹, other and more comprehensive studies, including proteomic and transcriptomic analysis, have not detected platelet Epac1^{12,13}. Furthermore, our group recently demonstrated that the extensively used Epac activator 8-pCPT-2'-O-Me-cAMP completely failed to activate platelet RAP1^{14,15}. Thus, Epac1 is not directly involved in platelet RAP1 activation nor is it likely to be expressed in platelets. However, it has been shown that Epac play a crucial role in hematopoietic cell generation¹⁶, but its role in thrombosis and hemostasis remains unknown. In the present investigation we have therefore used a global Epac1^{-/-} knockout mouse model for studies on platelet function, *in vivo* assays and quantitative label-free proteomics analyses to determine the potential roles of Epac1 in megakaryopoiesis, platelet activation, and hemostasis. We report here that Epac1^{-/-} mice have increased bleeding time, impaired secondary hemostasis, moderately increased platelet size, increased number of reticulated platelets and significantly changed expressions of several proteins, including up-regulated α IIB β 3-associated ILK and down-regulated plasma coagulation factors. Importantly, Epac1 deficiency also led to generation of megakaryocytes (MK) and platelets with severely reduced levels of platelet GPIb β , a subunit of the GPIb-IX-V receptor. This may affect the interaction of platelet GPIb-IX-V with the vessel wall at sites of vascular injury, and hence may be translated into defective platelet adhesion and impaired hemostasis under high shear conditions. Our viscoelastic measurements revealed that Epac1^{-/-} mice have a defective clotting process, a result corresponding well with our proteomics data showing reduced plasma levels of factor XIII and fibrinogen. We propose that the observed altered platelet phenotype is due to lack of Epac1 activity during megakaryocyte maturation. The defects in blood clotting for Epac1^{-/-} mice seems to be connected to secondary hemostasis.

Materials and Methods

Mouse strains. Mouse models: The Epac-deficient mouse models used in this study are described elsewhere¹⁷. In short, *loxP* sites were inserted by homologous recombination into the genes encoding Epac1 (*RapGEF3*) and Epac2 (*RapGEF4*) flanking exons 7–10 in *RapGEF3* and exons 12–13 in *RapGEF4*. These exons encode the cAMP-binding domain in both proteins. A Neomycin cassette flanked by *frt*-sites were used for screening purposes and thereafter excised. Epac1^{flxed/flxed} and Epac2^{flxed/flxed} mice were generated at the Mouse Clinical Institute, Strasbourg, France. In this study, mice globally deleted for Epac1 (Epac1^{-/-}) or all isoforms of Epac2 (Epac2^{-/-}) were produced by crossing floxed animals with mice expressing Cre recombinase from the cytomegalovirus (CMV)-promoter. The mice were bred against a C57BL/6J BomTac (Taconic, Denmark) genetic background for at least ten generations by the start of the study. Epac1^{-/-} and Epac2^{-/-} mice are healthy and apparently indistinguishable from WT mice under standard housing. The wild type C57BL/6J BomTac animals included were littermates and commercial mice (Taconic, Denmark). The animal experiments were approved by the Norwegian Animal Research Authority and conducted according to the European Convention for the Protection of Vertebrates Used for Scientific Purposes. Artificial lighting was maintained on a 12:12 hour light-dark cycle and room temperature was kept constant at 23 °C. All mice were housed in a pathogen-free facility with access to water and chow ad libitum.

Chemicals and reagents. Isoflurane was from Schering-Plough Animal Health (Kenilworth, NJ). PE Rat Anti-Mouse CD41, FITC RAT Anti-Mouse CD62P and FITC RAT Anti-Mouse CD45 was from BD Biosciences (Franklin Lakes, NJ). Thrombin was from Parke Davis (Morris Plains, NJ) and Type I Collagen (Vitrogen 100) from Angiotech BioMaterials (Palo Alto, CA). All other chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Bleeding time, hemoglobin measurement and whole blood clotting time tests. Mice were kept under isoflurane/O₂/NO₂ anesthesia and placed on a heating pad at 37 °C. For bleeding time determination, exactly 5 mm of the distal tip of the tail was amputated using a scalpel and the tail immediately submerged into 10 ml phosphate buffered saline (PBS) at 37 °C. The bleeding end point was the time when bleeding had ceased for at least 10 seconds. Bleeding was also quantified by measuring the resulting hemoglobin content in the PBS solution. For this, 1 ml RIPA buffer was added followed by sonication. Absorbance was read at 575 nm in an ASYS UVM340 plate reader with Digiread 1.2.0.2 software (Biochrom, Cambridge, UK). A whole blood clotting time test was performed on freshly drawn blood as described¹⁸.

Preparation of mouse platelets and plasma samples. Blood was obtained from mice euthanized with CO₂. Between 500–1000 μ l was drawn from the left ventricle into a 2 ml syringe, containing 100 μ l acid citrate dextrose (ACD), 200 μ l Ca²⁺-free Tyrode's solution (136 mM NaCl, 2.7 mM KCl, 0.77 mM NaH₂PO₄ × 2H₂O, and 2.0 mM MgCl₂ × 6H₂O, pH 7.3) 5 mM glucose and 0.05% bovine serum albumin. The blood was centrifuged at 300 × *g* for 5 minutes at room temperature (RT), and the resulting platelet-rich plasma centrifuged at 1000 × *g* for another 10 minutes in the presence of 10 μ l ACD. The supernatant was transferred to Eppendorf tubes and the pelleted platelets resuspended in Tyrode's buffer and adjusted to 3.5 × 10⁸ platelets/ml. For proteomic analyses, platelets were further purified by size-exclusion through Sepharose CL-2B gel (Pharmacia Biotec, Sweden) as described previously¹⁹.

Assessment of P-selectin translocation. Isolated mouse platelets (5 μ l) were added to polystyrene tubes containing FITC-conjugated anti-mouse CD62P (P-selectin) and PE-conjugated Anti-Mouse CD41 (integrin subunit: α IIB). Various concentrations of agonists (0.035–0.1 U/ml thrombin, 10–40 μ M ADP and 20–60 μ g/ml collagen) were added and the platelets were incubated for 15 minutes and then fixed in 0.2% paraformaldehyde (PFA). The level of P-selectin translocation was assessed by flow cytometry using a FACSCalibur (BD Biosciences,

Franklin Lakes, NJ) and FlowJo software (Tree Star, Inc., Ashland, OR). In brief, 5000 events were conservatively identified as platelets by adjusting forward- and side-scatter thresholds to exclude platelet-derived microparticles (PMPs, identification of PMPs was done as previously described¹⁵). The thrombopoietic marker CD41 and forward- and side-scatter distributions were then used to confirm the platelet population, before the level of P-selectin surface expression was scored as percentage of CD62P positive platelets.

Determination of platelet number. Blood (10 μ l) from the facial vein of live mice was drawn into ACD coated syringes and then fixed in 0.2% PFA. The fixed whole blood was incubated over night (O/N) with CD41 antibody before platelets were identified by both CD41 positivity and forward- and side- scatter by flow cytometry (FACSCalibur). The platelet populations were gated and data collected for 1 minute. The flow rate of the FACSCalibur combined with the dilution factor of the whole blood in fixative was used to calculate the number of platelets/ml.

Determination of reticulated platelets. The proportion of reticulated platelets in platelet-rich plasma (PRP) was measured using thiazole orange according to the method described by Hartley *et al.*²⁰. A FASC Accuri C6 (BD Biosciences, San Jose, CA, USA, Accuri Cytometry) was used to detect fluorescent platelets, and the data were analysed using the Accuri C6 Software (BD Biosciences). In brief, the proportion of reticulated platelets were determined by adjusting the gating for platelets which were positive for thiazole orange, but negative for the same platelets treated with RNase A prior to staining. The positive fraction in the RNase treated samples was subtracted to eliminate false positives.

Scanning electron microscopy. Platelets were treated with vehicle or 0.07 U/ml thrombin for 10 minutes before fixation and sample preparation as described²¹. Specimens were examined using a Jeol JSM-7400F scanning electron microscope with Jeol PC-SEM 7400 software (Jeol Ltd., Tokyo, Japan).

Preparation of mouse embryonic liver samples. Mice (8–10 weeks old) were euthanized by CO₂ at 2 weeks of gestation. The visceral yolk sac containing the embryos was excised from the uterus and immediately submerged in ice-cold PBS. Single embryos were isolated and placed in PBS in petri dishes. The tails were collected for sex determination by PCR using the following primers: Fragile X, sense 5'- GTGGCTTCTTCAACAATCTAACCCTAAT -3' and antisense 5'- CCATCTCCTGTGCCCTTTTAGCTAT'; UT-A1, SRY, sense 5'- GCCCTACAGCCACATGATATCTTAAAC -3' and antisense 5'- GAGGCAACTGCAGGCTGTAAAATG -3'. The embryonic livers were collected and fixed in Karnovsky's solution for 24 h followed by dehydration with graded alcohol solutions. The livers were embedded in Agar100 resin and 1 μ m thin sections were cut and stained with toluidine blue.

Determination of megakaryocyte number and morphology. Mice were euthanized with CO₂ and bone marrow cells isolated from femurs and tibias, by gently flushing the femoral or tibia interior with PBS into a sample vial²². Using flow cytometry (FACS Aria SORP, BD Biosciences, Franklin Lakes, NJ), megakaryocytes were identified by Hoechst33342 (nucleic stain) and positive staining for CD41, as well as negative signal for the erythrocyte marker CD45. For morphological studies, the bone marrow was smeared onto glass slides and stained with May-Grünwald-Giemsa. For quantification of megakaryocytes in mouse liver, the total megakaryocyte count from four to six sections from the same specimen was determined using light microscopy. The megakaryocytes were identified by their large and lobulated nuclei, their size and the pale cytoplasm surrounded by a demarcation membrane²³. The area of the sections was determined using ImageJ software²⁴, and average number of megakaryocytes per mm² was calculated.

Multiplate and ROTEM whole blood analysis. Murine whole blood samples for rotational thromboelastometry (ROTEM[®] *delta*, Tem International, Basel, Switzerland) was collected from the left ventricle into a 2 ml syringe as described above for platelet preparation, to a final concentration of 3.2% liquid sodium citrate (VACUETTE, Greiner Bio-One International GmbH, Kremsmunster, Austria). After 7 minutes incubation at 37 °C 300 μ l of citrated whole blood was analyzed after manufacturer's instructions with STARTEM, INTEM, EXTEM and FIBTEM liquid reagents (Tem International, Basel, Switzerland). The measuring time was increased to 90 minutes to obtain higher MCF values, but no other parameters were changed.

For whole blood aggregation analysis on the Multiplate[®] analyzer (Roche Diagnostics Ltd., Rotkreuz, Switzerland) 2 ml Lithium Heparin blood collection tubes (VACUETTE, Greiner Bio-One International GmbH, Kremsmunster, Austria) were used. After a minimum of 30 minutes resting period in room temperature, 300 μ l of whole blood was analyzed after manufacturer's instructions with ADPtest (Roche Diagnostics Ltd., Rotkreuz, Switzerland).

Sample preparation for proteomics. Plasma samples (150 μ g) were depleted for albumin using the Qproteome Murine Albumin Depletion Kit with spin columns as described by the manufacturer (Qiagen, Germantown, MD). Depleted samples (average 61 μ g) were desalted using four volumes of ice-cold acetone and incubated O/N at -20 °C. Protein concentrations in platelet and plasma samples were measured using the BCA Protein Assay Kit (Product # 23225, Pierce, Thermo Scientific, Rockford, IL) using a SpectraMax 96 well plate reader, SoftMax Pro Protein Quantitation and BCA software (Sunnyvale, CA). Platelet proteins (10 μ g total in SDS-sample buffer) were separated on a 10% SDS-polyacrylamide gel. The gel was sliced crosswise into 23 bands and digested in-gel with trypsin²⁵. The sample preparation is described in detail in the supplementary methods section (S5).

Mass spectrometry analysis of tryptic peptides using LC-MS. Tryptic peptides were injected into an Ultimate 3000 RSLC system (Thermo Scientific, Sunnyvale, CA) connected online with positive electrospray ionization on a LTQ-Orbitrap Velos Pro mass spectrometer (Thermo Scientific, Bremen, Germany). The tryptic plasma peptides (2.5 µg) were eluted with a 180 min biphasic acetonitrile (I) gradient from a 50 cm analytical column (Dionex #164570, Acclaim PepMap100 nanoViper column, 75 µm i.d. × 50 cm, packed with 3 µm C18 beads (Thermo Scientific)), whereas the tryptic platelet-derived peptides were separated with a 90 min gradient on a 15 cm analytical column (Acclaim PepMap 100, 15 cm × 75 µm i.d. nanoViper column, packed with 2 µm C18 beads). The eluting peptides were ionized in the electrospray and analysed by the LTQ-Orbitrap Velos Pro. The mass spectrometer was operated in the DDA-mode (data-dependent-acquisition) to automatically switch between full scan MS and MS/MS acquisition. The LC-MS analysis is described in detail in the Supplementary methods section.

Label-free protein quantification and data analysis. The software Progenesis LC-MS® Ver 2.6 (Nonlinear Dynamics Ltd, Newcastle, UK) and SearchGUI/PeptideShaker²⁶ were used for plasma protein quantification and identification, respectively. MaxQuant module with Andromeda^{27,28} (version 1.3.05) was used for platelet protein quantification and identification.

Data Availability. The raw LC-MS data have been deposited to the Proteome Xchange Consortium via the PRIDE²⁹ repository with dataset identifier PXD000282 and null. A detailed description of the label-free data analysis is given in the Supplementary methods section.

ELISA. The concentration of plasma Von Willebrand factor (vWF) was determined after mice had received an intra-peritoneal (i.p.) injection of 0.1 ml of either vehicle (0.9% NaCl) or the arginine vasopressin (AVP) analog dDAVP (1 ng/g bodyweight in 0.9% NaCl). After 1.5 h the mice were euthanized by CO₂ followed by immediate cardiac puncture to collect 0.4 ml blood into a 0.5 ml syringe with 0.1 ml ACD. Plasma was isolated from blood by centrifugation for 10 minutes at 1000 × g, and samples were analyzed using the Mouse Von Willebrand Factor ELISA Kit (antibodies-online Inc., ABIN2540487) according to the manufacturers instructions.

The levels of Gp1bβ and Gp1ba were detected from isolated mouse platelets or bone marrow aspirates using the quantitative sandwich enzyme immunoassay technique conducted in accordance with the manufacturers protocols (ABIN424559; Antibodies-online GmbH, Aachen, Germany and SEB108Hu; USCN Life Science Inc., Wuhan, China, respectively). The optical densities at 450 nm were measured using a Biochrom ASYS UVM340 Microplate Reader (Holliston, MA).

Statistics. Statistical significance was determined by analysis of variance (ANOVA) for multiple comparisons and the Student's *t*-test for pair-wise comparisons. Proteomics data were also subjected to a multivariate general linear model to reveal intra-group differences. All statistical analyses were done in IBM SPSS Statistics for Mac, (ver 19.0, IBM Corp.: Armonk, NY). Statistical significance was set to *P* < 0.05. Sample sizes are given for each figure.

Results

Mice lacking Epac1 have prolonged *in vivo* bleeding time and *ex vivo* whole blood clotting time. To determine whether Epac1 or Epac2 may be required for normal hemostasis *in vivo*, we conducted a tail-bleeding test. While the median bleeding time was less than 6 minutes for both WT and Epac2^{-/-} mice, 6 out of 7 Epac1^{-/-} mice bled beyond the 20 minutes duration of the assay (Fig. 1A). Short intermittent arrest of bleeding was observed in some Epac1^{-/-} mice, but duration was less than 10 seconds. The total blood loss, assessed by its hemoglobin content, corresponded closely with the observed bleeding time, both for Epac1^{-/-} and WT mice (Fig. 1B).

The prolonged *in vivo* bleeding time could be due to altered response of the vascular endothelium and surrounding stromal tissue to the tail cutting trauma or to inherent pre-existing differences of the circulating blood, or both. To know if the Epac1^{-/-} bleeding phenotype could be reproduced *ex vivo*, we compared the clotting time of whole blood from WT and Epac1-deficient mice. The clotting time was about 3-fold prolonged in Epac1^{-/-} mice compared to WT mice, suggesting that Epac1 deficiency decreases the inherent blood clotting capacity (Fig. 1C). Epac1 appears to be involved in cAMP-regulated Weibel-Palade body exocytosis of vWF into the blood or subendothelium^{6,30}. As vasopressin is able to rapidly induce such exocytosis, we determined plasma vWF concentrations for both resting state mice and mice injected with the vasopressin analog dDAVP^{6,30}. Using ELISA, we found a non-significant trend towards lower basal vWF plasma levels in Epac1^{-/-} compared to WT mice, both for resting state animals and animals receiving dDAVP (Fig. 1D)^{6,30}. Thus, Epac1 deficiency affects whole blood clotting *ex vivo*, mainly through other mechanisms than via vWF.

Epac1^{-/-} mice have fewer, younger and larger blood platelets that react with strong P-selectin externalization to thrombin, ADP and collagen. The platelets from Epac1^{-/-} mice had normal shape and surface morphology, as revealed by scanning electron microscopy. They had discoid shape and visible pores to the open canalicular system (OCS) in the resting state. Upon stimulation with thrombin, which caused transformation from individual platelets to aggregates, the platelets underwent the typical surface convolution with pseudopod extensions (Fig. 2A).

However, a mild macrothrombocytopenia was observed. In the resting state, Epac1^{-/-} platelets had 11% longer diameter than WT platelets (Fig. 2B), and the number of circulating platelets was slightly reduced (about 7%) in the Epac1^{-/-} mouse blood compared to WT (Fig. 2C). We also observed a higher ratio of reticulated platelets in Epac1^{-/-} mice (Fig. 2D–F), suggesting increased thrombopoiesis. However, these subtle differences are




Figure 1. Epac1^{-/-} mice have increased bleeding time. **(A)** Tail bleeding time in WT (n = 8), Epac1^{-/-} (n = 7) and Epac2^{-/-} (n = 8) mice. Each point represents the measurement from one mouse. The horizontal dotted lines represent average tail bleeding time. 1200 seconds marks the experimental end point. **(B)** Blood loss quantified as amount of hemoglobin (absorbance at 575 nm) released during the tail bleeding test in WT (n = 8) and Epac1^{-/-} mice (n = 7). **(C)** Whole blood clotting time in WT (n = 6) and Epac1^{-/-} (n = 7) mice. **(D)** The plasma levels of vWF, determined by ELISA, 1.5 h after i.p. injection of 0.9% NaCl in WT (n = 4) and Epac1^{-/-} mice (n = 5), or of dDAVP (1 ng/g bodyweight) in WT (n = 4) and Epac1^{-/-} mice (n = 5). The values shown are mean ± SEM. NS = not significant, **P* < 0.05, ****P* < 0.005 ANOVA (A) and Student's t-test (B, C, D).

presumably of insufficient magnitude to explain the observed bleeding and clotting abnormalities in the Epac1^{-/-} mice^{31,32}.

To address this question, we investigated therefore if the Epac1^{-/-} mouse platelets had impaired sensitivity to thrombin, ADP or collagen, using agonist-induced P-selectin translocation as marker. Surprisingly, platelets derived from Epac1^{-/-} mice had increased responsiveness to all concentrations of thrombin, ADP and collagen tested (Fig. 2G–I), apart from the lowest thrombin concentration, which induced equal P-selectin translocation in platelets from Epac1^{-/-} and WT mice (Fig. 2G). The relative sensitivity of Epac1^{-/-} mouse platelets was strongest (up to 3-fold) at high ADP concentrations (Fig. 2H). In spite of this, we found a decrease in ADP-induced platelet aggregation in whole blood for the Epac1^{-/-} platelets compared to WT platelets (Fig. 2K). In conclusion, Epac1-deficient mice have a decreased number of slightly enlarged platelets with increased agonist-induced α-granule secretion, but decreased aggregation, compared to WT platelets.

Adult and fetal Epac1^{-/-} mice have increased number of megakaryocytes. We considered that the Epac1^{-/-} platelet abnormalities could be caused by altered megakaryopoiesis. The MKs from Epac1^{-/-} mice




Figure 2. Epac1^{-/-} mice have fewer, but more reticulated platelets and more agonist-responsive blood platelets than WT mice. (A) Scanning electron micrographs of resting and thrombin-activated platelets from WT and Epac1^{-/-} mice. The platelets had been incubated for 10 min with vehicle (control) or 0.07 U/ml thrombin. The bars represent 1 μm. OCS: open canalicular system. (B) The average platelet diameter of resting platelets from WT and Epac1^{-/-} mice (WT: n = 3 mice with 28 platelet diameters measured, Epac1^{-/-}: n = 3 mice with 26 platelet diameters measured.) (C) Platelets from WT (n = 9) and Epac1^{-/-} (n = 10) mice were identified and counted by flow cytometry using the platelet specific marker CD41 and forward- and side scatter. (D,E,F) Reticulated platelet count in platelet-rich plasma from WT and Epac1^{-/-} mice. Platelets were stained with thiazole orange without (D) or with (E) RNase treatment prior to staining. The platelets were then analyzed by flow cytometry, and the percent of reticulated platelets determined as described in the methods section. (F): Box-plot showing the reticulated platelet fraction from WT- and Epac1^{-/-} mice. The data are average of three mice from each group. P = 0.068, Student's t-test. Platelets from Epac1^{-/-} or WT mice were exposed to various concentrations of thrombin (G), ADP (H) or collagen (I), and analyzed for P-selectin externalization by flow

cytometry. Data shown are average \pm SEM from three independent experiments. (J) The gating strategy for the flow cytometric analyses, including histogram (right panel) showing a shift in mean fluorescence intensity after treatment with 0.1 U/ml Thrombin (light grey). Dark grey: unstimulated platelets (K) Whole blood from WT (n = 8) and *Epac1*^{-/-} (n = 8) mice were used in an ADP-induced aggregation assay. Data shown are average \pm SEM. OCS; open canalicular system. P; platelets. P-sel. +; P-selectin positive. **P* < 0.05, ***P* < 0.01, ****P* < 0.005, Student's t-test.

bone marrow aspirates appeared normal, with large lobulated nuclei (Fig. 3A). However, the relative MK number compared to normal bone marrow cells was higher in *Epac1*^{-/-} mice than in the WT mice (Fig. 3B and C). Since the liver is the main hematopoietic tissue in the embryo, we also examined the morphology and MK count in embryos harvested at 14 days after gestation. As with the bone marrow MKs, we found no apparent difference in the morphology of embryonic MKs between the *Epac1*^{-/-} and WT-mice. Both genotypes had typical MK morphology, which were significantly larger than the liver parenchymal cells, with lobulated nuclei, and a marked demarcation membrane²³ surrounding a pale cytoplasm scattered with pre-platelets (Fig. 3D). In both bone-marrow smears and embryonic liver sections we failed to identify morphological features associated with malfunction, such as hyperplasia and hyperchromatic nuclei, increased polyploidy, or hypolobulated nuclei, as reviewed in³³. Also *Epac1*^{-/-} embryos had higher MK count in the hematopoietic tissue compared to the WT embryo (Fig. 3E). We conclude that *Epac1*-deficient mice have increased number of morphologically grossly normal MKs both in fetal and adult life.

Epac1-deficient mice have moderately altered plasma levels of several coagulation factors. As a consequence of platelet aggregation at sites of vascular injury, the coagulation cascade is activated, generating thrombin which stabilizes the hemostatic plug by cross-linking fibrin³⁴. We analyzed therefore plasma by quantitative proteomics (see Supplementary Tables S1–S3 for all identified and quantified plasma proteins.). We detected a modest, but significant, decrease of several coagulation factors in *Epac1*^{-/-} plasma, including factors belonging to the intrinsic (factor IX) as well as the common (prothrombin, factor V, fibrinogen γ and β , factor XIIIa) coagulation pathways (Table 1 and Fig. 4). As the liver is the main producer of the coagulation factors, we also measured the plasma concentration of albumin. We found identical levels of albumin in *Epac1*^{-/-} and WT mice, suggesting that the decreased coagulation factor levels in *Epac1*^{-/-} mice are not a result of liver failure.

Epac-deficient mice have delayed rate of clot formation and decreased clot stability. During the tail-bleeding test on *Epac1*^{-/-} mice we noticed that bleeding ceased and then rapidly re-commenced several times, indicating the formation of short-lived, abortive hemostatic plugs. We conducted rotational thromboelastometry (ROTEM) assays to assess the clot strength and stability in whole blood, where platelets and coagulation factors are present together in physiological relevant proportion. Samples from WT and *Epac1*^{-/-} mice were compared by INTEM (Fig. 5A), EXTEM (Fig. 5B) and FIBTEM (Fig. 5C) analysis to test the function of the primary and the secondary hemostasis. We found that the clotting time (CT), defined as the time from start of activation to start of coagulation, was prolonged for *Epac1*^{-/-} samples for both tests. The same trend was observed for the rate of blood clot formation (CFT, clot formation time until 20 mm amplitude reached). The maximum clot firmness (MCF) was lower for *Epac1*^{-/-} compared to WT samples. When a poor EXTEM is compared to a normal FIBTEM, this would indicate deficient platelet function or low platelet numbers. To compare CT and MCF without the influence of platelets we assessed FIBTEM in the presence of the actin polymerization and platelet activation blocker cytochalasin D. Under such conditions, even with only one platelet inhibitor³⁵ the FIBTEM data for *Epac1*^{-/-} mice showed very low values for MCF, thus suggesting that without platelets present there will be very little or no clot formation. The FIBTEM assay is highly affected by the expression level of fibrinogen and factor XIII, which we found significantly down-regulated in the proteomics data (Table 1 and Fig. 5). Thus, our results suggests that the defects in blood clotting for *Epac1*^{-/-} mice are caused by impaired secondary hemostasis.

Platelets from *Epac1*^{-/-} deficient mice have increased ILK and imbalanced expression of important GPIb-IX-V receptor proteins. To search for an explanation for the apparently contradictory α -granule activation reactivity of *Epac1*^{-/-} platelets (Fig. 2D–F) and the prolonged bleeding (Fig. 1A) we used label-free quantitative proteomics on platelet samples. We found that several proteins involved in platelet activation were differentially expressed in *Epac1*^{-/-} and WT mice derived platelets (Table 2 and Supplementary Table S4). We found that *Epac1*^{-/-} platelets had up-regulated α IIB β 3-associated protein Integrin linked protein kinase (ILK). This kinase is required for agonist-induced α -granule secretion, which was increased in the platelets from our *Epac1*^{-/-} mice (Fig. 2), and is known to be dramatically decreased in ILK-deficient mice³⁶.

Another finding was strong down-regulation of the transmembrane protein GPIb β , with unaltered expression of the GPIb α (Table 2) and 3-fold increase of GPV (Table 2). In platelets, 2 GPIb β subunits are linked through disulfide bonds to 1 GPIb α subunit, forming a complex known as GPIb, which in turn interacts noncovalently with GPIX and GPV to generate the glycoprotein (GP) Ib-IX-V receptor complex³⁷. The expression of GPIb α subunit was not altered, whilst the expression of GPV subunit was 3-fold increased. The GPIX subunit was only identified in the WT fraction, and could thus not be quantified.

Quantitative sandwich ELISA assays helped verify the proteomic data and establish the stoichiometry of GPIb β and GPIb α . In accordance with the proteomic data, the ELISA assay targeting GPIb β showed a 4-fold down-regulation in *Epac1*^{-/-} platelets compared to WT (Fig. 6A), while the ELISA assay targeting GPIb α showed similar levels of GPIb α in WT and *Epac1*^{-/-} platelets (Fig. 6B). The ELISA assays also enabled quantification of the GPIb β and GPIb α concentrations, and we found the WT platelet concentration of GPIb β to be double that




Figure 3. Increased number of megakaryocytes in adult bone marrow and embryonic liver. Representative micrographs of May-Grünwald Giemsa stained bone marrow megakaryocytes from WT and *Epac1*^{-/-} mice. **(B)** Flow cytometric determination of bone marrow megakaryocytes numbers in *Epac1*^{-/-} (n = 9) and WT (n = 10) mice. **(C)** Flow cytometric scatter plots with the gating strategy used to obtain data in B are shown. **(D)** Toluidine-stained sections of mouse embryonic livers showing megakaryocytes. Arrowheads indicate demarcation membrane. **(E)** Number of megakaryocytes per mm² in livers from WT (n = 5) and *Epac1*^{-/-} (n = 7) embryos (E14). Data are average and \pm SEM. LN; lobulated nucleus, BMP; bone marrow population, NBMC; nucleated bone marrow population, MK; megakaryocytes. * $P < 0.05$, *** $P < 0.005$, Student's t-test. The bars indicate 20 μ m in A and D.

Protein	Protein coverage (%)	Number of peptides	Ratio KO/WT	SEM	P (ANOVA)
Coagulation factor XII	28.3	29	0.96	0.0183	0.064
Coagulation factor IX	15.9	6	0.78	0.0521	0.003
Coagulation factor X	16.6	10	0.95	0.0428	0.403
Prothrombin	40.6	42	0.80	0.0169	0.000
Coagulation factor V	15.9	29	0.83	0.0236	0.000
AntiThrombin-III	51.8	55	0.94	0.0217	0.029
Fibrinogen γ	68.3	63	0.74	0.0189	0.000
Fibrinogen β	58.8	81	0.72	0.0167	0.000
Coagulation factor XIIIa	26.9	25	0.87	0.0260	0.001
Coagulation factor XIIIb	20.5	16	1.12	0.0433	0.023
Fibronectin	30.4	117	0.81	0.0119	0.000

Table 1. Differentially regulated plasma proteins detected by proteomics.




Figure 4. Key components of the intrinsic coagulation cascade are down-regulated in *Epac1*^{-/-} plasma. Plasma samples from WT (n = 6) and *Epac1*^{-/-} (n = 7) mice were analyzed by label-free quantitative proteomics. The differentially expressed proteins in the plasma samples were involved in the coagulation cascade and formation of fibrin clots. Down-regulated proteins are red, up-regulated are blue. Green, no altered regulation. Grey, not quantified. Thrombin signaling in this cascade is marked with green arrows.

of the WT and *Epac1*^{-/-} platelet concentrations of GPIb α . The WT, but not the *Epac1*^{-/-}, platelet concentrations of GPIb β and GPIb α is in accordance with the known formation of the GPIb complex, where the ratio of these subunits is 2:1, respectively³⁷.

We estimated also the megakaryocyte GPIb β levels by ELISA of bone marrow extract. The GPIb β content was lower in *Epac1*^{-/-} derived bone marrow extract (Fig. 6D) suggesting that the deficiency was present already during megakaryopoiesis, and that *Epac1* is required already at this stage to support full GPIb β expression. Since platelet aggregation depends on α IIB β 3, we quantified also the expression of α IIB β 3 by ELISA. As shown in Fig. 6C, similar levels of α IIB β 3 were observed in *Epac1* and WT derived platelets.




Figure 5. *Epac1*^{-/-} mice exhibit a delayed rate of clot formation and fragile clot stability *ex vivo*. ROTEM characterization of the coagulation process in citrated whole blood from WT and *Epac1*^{-/-} mice. Activated CT: clotting time i.e., the latency until the clot reaches a firmness of 2 mm, CFT: clot formation time and MCF: maximum clot firmness in mm was assessed by ROTEM assays (A) INTEM, (B) EXTEM and (C) FIBTEM. In FIBTEM assays the actin polymerization and platelet activation blocker cytochalasin D is present. Each point represents the measurements of one mouse. The horizontal dotted lines represent the median, n = 5–11 mice per group. **P* < 0.05, ***P* < 0.01, Student's t-test.

Protein	Part of/associated with complex	Unique peptides	Intensity WT	Intensity Epac1 ^{-/-}	Ratio KO/WT	PEP value
GPIb α	GPIb-IX-V	5	9373800	9188200	0.98	2.21E-10 ⁶
GPIb β	GPIb-IX-V	2	7048600	919540	0.13	3.68E-72
GPIX	GPIb-IX-V	1	1253500	n.f.	—	0.0013581
GPV	GPIb-IX-V	6	5321700	16134000	3.03	1.57E-79
ILK	Integrin α IIb β 3	5	1686400	6406100	3.80	2.73E-12

Table 2. The impact of Epac1 deletion on expression of ILK and GPIb-related platelet adhesion proteins, detected by proteomics. ILK, integrin linked protein kinase, GP, glycoprotein.




Figure 6. Decreased platelet levels of GP1b β and un-altered levels of GP1b α in Epac1^{-/-} mice. Quantification of GP1b β (A), GP1b α (B) and α IIb β 3 (C) of platelets from WT (n = 8) and Epac1^{-/-} (n = 8) mice by ELISA. Each dot represents the data from a single mouse. (D) Quantification of megakaryocyte GP1b β by ELISA from WT (n = 3) and Epac1^{-/-} (n = 3) mice. The horizontal dashed lines represent the mean. *** P < 0.005.

Discussion

The present study demonstrates that *Epac1*^{-/-} mice have: (1) prolonged bleeding time; (2) impaired clotting connected to secondary hemostasis; (3) fewer, larger and more *in vitro* P-selectin responding platelets; (4) increased number of reticulated platelets (5); increased number of MKs in adult bone marrow and embryonic liver (6); decreased aggregatory platelets response in whole blood. Several of these observations can be explained by the feedback loop between the platelets and their megakaryocyte precursors^{38,39}. If the demand for circulating platelets increases, for instance following blood loss or increased consumption of platelets, the MKs proliferate to produce platelets to compensate the loss. These newly produced platelets are larger and more reactive than older circulating platelets^{40,41}.

To probe the molecular basis for our observations, we performed label-free quantitative proteomics on plasma and platelet samples to identify proteins with irregular expression in *Epac1*^{-/-} mice. Several proteins involved in the coagulation cascade (coagulation factor IX, V, XIIIa, prothrombin) and the cross-linking fibrin clot formation system (fibrinogen γ and β , fibronectin) were moderately downregulated in *Epac1*^{-/-} mice plasma samples, compatible with an intravascular coagulation (DIC)-like effect with increased consumption of coagulation factors⁴². While these findings are expected consequences of increased bleeding, it is not obvious how they occur in the first place. The *Epac1*^{-/-} mice breed normally, are healthy and apparently indistinguishable from WT littermates. Their fecal matter shows no hemoglobin, and there are no signs of petechiae on skin or mucous membranes to suggest spontaneous bleeding. Thus, it seems it is only after being challenged that their bleeding phenotype becomes evident.

We found differentially expressed proteins also in the *Epac1*^{-/-} platelet samples. They belong to, or are associated with, platelet receptors (ILK, GPIb β , GPV). The platelet receptor protein GPIb β , which is drastically down-regulated in the *Epac1*^{-/-} platelets, is part of the adhesion platelet receptor complex GPIb-IX-V. The interaction between GPIb-IX-V and ECM-associated vWF is sufficiently rapid to allow for transient binding of platelets under conditions of high shear stress⁴³. Deficient or nonfunctioning GPIb-IX-V is characteristic of the inherited bleeding disorder BSS⁴⁴, which shares several of the symptoms observed in the *Epac1*^{-/-} mice, such as increased bleeding time, lower platelet counts and larger platelets^{4,45,46}. Decreased platelet counts and increased platelet size in patients with BSS have been reported to be similar regardless of which GPIb-IX-V -subunit is affected. Also, in accordance with our findings for *Epac1*^{-/-} mice (Figs 1A–C, 2C), the bleeding diathesis in BSS patients has been shown to be more severe than expected from the platelet counts⁴⁷. In line with this, a study by Kato *et al.* clearly shows that genetic deletion of mouse platelet GPIb β -component produces a Bernard-Soulier phenotype. The GPIb β knockout mice exhibited a severe bleeding phenotype, macrothrombocytopenia and contained enlarged α -granules⁴⁸. Our thromboelastometry analysis (INTEM and EXTEM) showed that 1) the rate of blood clot formation in *Epac1*^{-/-} mice is delayed and 2) the clot is smaller and the clot stability is more fragile (lower MCF) compared to WT mice (Fig. 5). MCF is an indirect index of blood clot retraction and thus related to platelet contractile force. Reduction in platelet contractile force has been shown to correlate with reduced expression of GPIb β and postoperative blood loss for cardiac surgery patients^{49,50}. The difference between WT and *Epac1*^{-/-} mice regarding clot retraction persisted when platelet activation was blocked, suggesting that also other aspects than platelet contraction contributed to the deficiency. The low values for CT and MCF with the FIBTEM test for *Epac1*^{-/-} mice indicate that the plasma levels of fibrinogen and factor XIII may be responsible for the observed dysfunction of the clotting process. Furthermore, the decreased abundance of fibrinogen may contribute to the observed inhibited aggregatory effect in *Epac1*^{-/-} mice. Thus, the defects in blood clotting for *Epac1*^{-/-} mice seems to be connected to secondary hemostasis.

GPIb α is the main ligand binding subunit of GPIb-IX-V, with both GPIb β and GPIIX regulating its function and expression. Studies by Strasser *et al.* show that covalent binding between GPIb β and GPIb α is necessary to render the vWF binding sites of GPIb α functional⁴⁴, and others report that the intracellular region of GPIb β rather than GPIb α is critical for vWF-induced signaling^{51,52}. Strasser *et al.* also suggest that GPIb β is required for stabilizing GPIIX, which seems highly susceptible to proteolytic degradation when GPIb β is not present⁴⁴. The fact that GPIIX was not detected in the *Epac1*^{-/-} platelets is in accordance with such a mechanism. However, we found GPIb α levels in *Epac1*^{-/-} platelets to be unaltered. Both GPIIX and GPIb β are reported to be required for efficient plasma membrane expression of GPIb α ⁵³. GPIb β and GPIIX interact and together act as a chaperone for GPIb α , transporting it through the membrane systems of the maturing megakaryocyte and onto the surface of newly formed platelets⁴⁴. The non-regulated level of GPIb α in combination with the severely down-regulated GPIb β reported here is puzzling and indicates that *Epac1* may act more broadly than by decreasing GPIb β in the megakaryocytes.

The GPV subunit was up-regulated in the *Epac1*^{-/-} platelets, but this protein is not necessary for GPIb α and GPIb β expression and function in platelets⁵⁴. Interestingly, GPV knockout mice have shorter bleeding time and hyper-responsive platelets⁵⁵. Thus, GPV seems to be a negative modulator of platelet function, and may contribute to the observed bleeding phenotype in our *Epac1*^{-/-} mice.

The binding of vWF to the GPIb-IX-V complex initiates a signal that culminates in the activation of the integrin receptor α IIb β 3^{56,57}. Interestingly, the α IIb β 3-associated protein ILK is up-regulated in *Epac1*^{-/-} mice. ILK induces conformational changes in the extracellular part of α IIb β 3 that results in higher affinity for fibrinogen and vWF, thus facilitating platelet-platelet interactions and aggregation^{36,58,59}. While ILK deficient platelets have decreased agonist-induced α -granule secretion³⁶, our *Epac1*^{-/-} platelets have increased agonist-induced α -granule secretion (Table 2), in accordance with their increased ILK level. The up-regulated ILK and α -granule secretion levels may be a compensatory response for malfunctioning GPIb-IX-V adhesion *in vivo*.

Taken together, these results indicate that there may be a direct relationship between platelet levels of ILK and α -granule secretion. The increased α -granule secretion in *Epac1*^{-/-} platelets stands in contrast to exocytosis studies in other cell types, where *Epac1* has been found to be required for secretion⁶. A direct link between *Epac1* and “inside-out” Rap1-mediated signaling through other integrin receptors than α IIb β 3 has been established in

several cell types, such as monocytes¹¹ and ovarian carcinoma cells^{60,61}. However, we have previously used the well-known Epac1 agonist 8-pCPT-2'-O-Me-cAMP to study RAP1 activation in human platelets¹⁴. In sharp contrast to our results from other cell types^{62,63}, this agonist completely failed to activate platelet RAP1¹⁴. This result, taken together with comprehensive proteomic and transcriptomic analysis from other groups, strongly suggests that Epac1 is not present in platelets^{11,12}. Thus, we believe that our findings with regards to platelet function and signaling in the Epac1^{-/-} mice is not a direct result of loss of Epac1 activity in platelets. Moreover, as platelets are anucleate and have limited synthesis of new proteins, the differential expression of proteins in the Epac1^{-/-} platelets probably arises from the lack of Epac1 signaling in other cells of the hemopoietic platelet lineage. Our results showing that the level of Gβ1β3 is also reduced in the megakaryocytes supports this. Furthermore, Epac has important functions in several cell types of the vascular niche, including CD34⁺ hematopoietic stem cells, mesenchymal stem cells and pluripotent stem cells^{16,64}. Crucial roles of Epac signaling in hematopoietic cell generation were recently demonstrated¹⁶. Moreover, developmental differences in megakaryopoiesis and platelet generation can be determined by the bone marrow niche, including stromal cells and gradient of cytokines and growth factors⁶⁵. Thus, regulation of megakaryopoiesis and functional platelet synthesis is a complex process regulated at multiple phases in which we here show that Epac1 plays a key role. To our knowledge, we here provide the first direct evidence of an important role for Epac1 in secondary hemostasis. Our data also suggests a model where Epac1 is required for normal megakaryopoiesis and the subsequent expression of several proteins involved in key platelet functions, but where Epac1 itself is not present nor directly participates in signaling in mature circulating platelets.

References

- Broos, K., Feys, H. B., De Meyer, S. F., Vanhoorelbeke, K. & Deckmyn, H. Platelets at work in primary hemostasis. *Blood Rev* **25**, 155–167 (2011).
- Ruggeri, Z. M. Platelet adhesion under flow. *Microcirculation* **16**, 58–83 (2009).
- Jackson, S. P. Arterial thrombosis—insidious, unpredictable and deadly. *Nat Med* **17**, 1423–1436 (2011).
- Lopez, J. A., Andrews, R. K., Afshar-Kharghan, V. & Berndt, M. C. Bernard-Soulier syndrome. *Blood* **91**, 4397–4418 (1998).
- Birkeland, E. *et al.* Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. *J Proteomics Bioinformatics* **2**, 244–254 (2009).
- van Hooren, K. W. *et al.* The Epac-Rap1 signaling pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells. *J Biol Chem* **287**, 24713–24720 (2012).
- de Rooij, J. *et al.* Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* **396**, 474–477 (1998).
- Grandoch, M., Roscioni, S. S. & Schmidt, M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. *Br J Pharmacol* **159**, 265–284 (2010).
- Dao, K. K. *et al.* Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. *J Biol Chem* **281**, 21500–21511 (2006).
- Smolenski, A. Novel roles of cAMP/cGMP-dependent signaling in platelets. *J Thromb Haemost* **10**, 167–176 (2012).
- Lorenowicz, M. J., van Gils, J., de Boer, M., Hordijk, P. L. & Fernandez-Borja, M. Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis. *J Leukoc Biol* **80**, 1542–1552 (2006).
- Zeiler, M., Moser, M. & Mann, M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. *Mol Cell Proteomics* **13**, 3435–3445 (2014).
- Bernardi, B. *et al.* The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIb beta3. *Blood* **107**, 2728–2735 (2006).
- Herfindal, L. *et al.* Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. *Biochem Biophys Res Commun* **437**, 603–608 (2013).
- Nygaard, G. *et al.* Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression. *Biochem Biophys Res Commun* **449**, 357–363 (2014).
- Carmona, G., Chavakis, E., Koehl, U., Zeiher, A. M. & Dimmeler, S. Activation of Epac stimulates integrin-dependent homing of progenitor cells. *Blood* **111**, 2640–2646 (2008).
- Kopperud, R. K. *et al.* Increased microvascular permeability in mice lacking Epac1 (Rapgef3). *Acta Physiol (Oxf)* **219**, 441–452 (2017).
- Dotson, R. L., Leveson, J. E. & Marengo-Rowe, A. J. & JE, U. Hemostatic Parameters of the Blood of Cotton Rats, *Sigmodon hispidus*, Infected with *Paratstrongylus costaricensis* (Metastrongyloidea: Angiostrongyloidea). *Trans Am Microscop Soc* **109**, 399–406 (1990).
- Selheim, F., Froyset, A. K., Strand, I., Vassbotn, F. S. & Holmsen, H. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLN: role of secreted ADP. *FEBS Lett* **485**, 62–66 (2000).
- Hartley, P. S. *et al.* Timed feeding of mice modulates light-entrained circadian rhythms of reticulated platelet abundance and plasma thrombopoietin and affects gene expression in megakaryocytes. *Brit J Haematol* **146**, 185–192 (2009).
- Jensen, B. O., Selheim, F., Doskeland, S. O., Gear, A. R. & Holmsen, H. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. *Blood* **104**, 2775–2782 (2004).
- Pitchford, S. C., Lodie, T. & Rankin, S. M. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. *Blood* **120**, 2787–2795 (2012).
- Cramer, E. M. *et al.* Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. *Blood* **89**, 2336–2346 (1997).
- Rasband, W. S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, <https://imagej.nih.gov/ij/>, 1997–2016.
- Oveland, E. *et al.* Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. *Leuk Res* **33**, 276–287 (2009).
- Barsnes, H. *et al.* compomics-utilities: an open-source Java library for computational proteomics. *BMC Bioinformatics* **12**, 70 (2011).
- Vaudel, M., Barsnes, H., Berven, F. S., Sickmann, A. & Martens, L. SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. *Proteomics* **11**, 996–999 (2011).
- Cox, J. *et al.* Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res* **10**, 1794–1805 (2011).
- Vizcaino, J. A. *et al.* The PRoteomics IDentifications (PRIDE) database and associated tools: status in 2013. *Nucleic Acids Res* **41**, D1063–1069 (2013).
- Voorberg, J., Bioerings, R., Fernandez, M. & Mcan Mourik, J. A. Epac Is Involved in cAMP-Mediated Exocytosis of Weibel-Palade Bodies in Endothelial Cells through the Activation of the Small GTPase Rap1. *Blood* **110**, 2157 (2007).
- Del Vecchio, A., Latini, G., Henry, E. & Christensen, R. D. Template bleeding times of 240 neonates born at 24 to 41 weeks gestation. *J Perinatol* **28**, 427–431 (2008).
- Martin, J. F., Trowbridge, E. A., Salmon, G. & Plumb, J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. *Thromb Res* **32**, 443–460 (1983).

33. Bianchi, E., Norfo, R., Pennucci, V., Zini, R. & Manfredini, R. Genomic landscape of megakaryopoiesis and platelet function defects. *Blood* **127**, 1249–1259 (2016).
34. Yip, J., Shen, Y., Berndt, M. C. & Andrews, R. K. Primary platelet adhesion receptors. *IUBMB Life* **57**, 103–108 (2005).
35. Lang, T. *et al.* Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. *J Thromb Haemost* **2**, 147–153 (2004).
36. Tucker, K. L. *et al.* A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. *Blood* **112**, 4523–4531 (2008).
37. Luo, S. Z. *et al.* Glycoprotein Ibalpha forms disulfide bonds with 2 glycoprotein Ibbeta subunits in the resting platelet. *Blood* **109**, 603–609 (2007).
38. Kuter, D. J. & Rosenberg, R. D. Regulation of megakaryocyte ploidy *in vivo* in the rat. *Blood* **75**, 74–81 (1990).
39. Kimura, Y. *et al.* Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis. *J Exp Med* **195**, 941–952 (2002).
40. Varol, E., Ozaydin, M., Turker, Y. & Alaca, S. Mean platelet volume, an indicator of platelet activation, is increased in patients with mitral stenosis and sinus rhythm. *Scand J Clin Lab Invest* **69**, 708–712 (2009).
41. Tschöepe, D. *et al.* Large platelets circulate in an activated state in diabetes mellitus. *Semin Thromb Hemost* **17**, 433–438 (1991).
42. Levi, M. & Ten Cate, H. Disseminated intravascular coagulation. *N Engl J Med* **341**, 586–592 (1999).
43. Nuyttens, B. P., Thijs, T., Deckmyn, H. & Broos, K. Platelet adhesion to collagen. *Thromb Res* **127**(Suppl 2), S26–29 (2011).
44. Strassel, C. *et al.* A novel missense mutation shows that GPIIb/IIIa has a dual role in controlling the processing and stability of the platelet GPIIb/IIIa adhesion receptor. *Biochemistry* **42**, 4452–4462 (2003).
45. Kunishima, S., Kamiya, T. & Saito, H. Genetic abnormalities of Bernard-Soulier syndrome. *Int J Hematol* **76**, 319–327 (2002).
46. Bernard, J. & Soulier, J. P. Sur une nouvelle variété de dystrophie thrombocytaire-hémorragique congénitale. *Semin Hop Paris* **3217**, (1948).
47. Savoia, A. *et al.* Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. *Haematologica* **96**, 417–423 (2011).
48. Kato, K. *et al.* Genetic deletion of mouse platelet glycoprotein Ib beta produces a Bernard-Soulier phenotype with increased alpha-granule size. *Blood* **104**, 2339–2344 (2004).
49. Greulich, P. E. *et al.* Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. *Thromb Res* **105**, 523–529 (2002).
50. Radicioni, M., Mezzetti, D., Del Vecchio, A. & Motta, M. Thromboelastography: might work in neonatology too? *J Matern Fetal Neonatal Med* **25**(Suppl 4), 18–21 (2012).
51. Maurer, E. *et al.* Targeting Platelet GPIIb/IIIa Reduces Platelet Adhesion, GPIIb Signaling and Thrombin Generation and Prevents Arterial Thrombosis. *Arterioscler Thromb Vasc Biol* **33**, 1221–1229 (2013).
52. David, T. *et al.* The platelet glycoprotein GPIIb/IIIa intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. *J Thromb Haemost* **8**, 1077–1087 (2010).
53. Lopez, J. A., Leung, B., Reynolds, C. C., Li, C. Q. & Fox, J. E. Efficient plasma membrane expression of a functional platelet glycoprotein Ib-IX complex requires the presence of its three subunits. *J Biol Chem* **267**, 12851–12859 (1992).
54. Kahn, M. L. *et al.* Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. *Blood* **94**, 4112–4121 (1999).
55. Ramakrishnan, V. *et al.* Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. *Proc Natl Acad Sci USA* **96**, 13336–13341 (1999).
56. De Marco, L., Girolami, A., Russell, S. & Ruggeri, Z. M. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. *J Clin Invest* **75**, 1198–1203 (1985).
57. Savage, B., Almus-Jacobs, F. & Ruggeri, Z. M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* **94**, 657–666 (1998).
58. Matheij, N. J. *et al.* Dual Mechanism of Integrin alphaIIb beta3 Closure in Procoagulant Platelets. *J Biol Chem* **288**, 13325–13336 (2013).
59. Haling, J. R., Monkley, S. J., Critchley, D. R. & Petrich, B. G. Talin-dependent integrin activation is required for fibrin clot retraction by platelets. *Blood* **117**, 1719–1722 (2011).
60. Enserink, J. M. *et al.* The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. *J Biol Chem* **279**, 44889–44896 (2004).
61. Rangarajan, S. *et al.* Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. *J Cell Biol* **160**, 487–493 (2003).
62. Christensen, A. E. *et al.* cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. *J Biol Chem* **278**, 35394–35402 (2003).
63. Enserink, J. M. *et al.* A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. *Nat Cell Biol* **4**, 901–906 (2002).
64. Saxena, S., Ronn, R. E., Guibentif, C., Moraghebi, R. & Woods, N. B. Cyclic AMP Signaling through Epac Axis Modulates Human Hemogenic Endothelium and Enhances Hematopoietic Cell Generation. *Stem Cell Reports* **6**, 692–703 (2016).
65. Slayton, W. B. *et al.* Developmental differences in megakaryocyte maturation are determined by the microenvironment. *Stem Cells* **23**, 1400–1408 (2005).

Acknowledgements

We thank Nina Lied Larsen, Olav Mjaavatten, Marianne Enger, Anne Nyhaug and Endy Spriet for excellent technical assistance. The SEM studies were performed at the Molecular Imaging Center (Fuge, Norwegian Research Council), University of Bergen. The proteomic studies were performed at the Proteomics Unit at the University of Bergen. The multiplate and ROTEM whole blood analysis were performed at the Department of Immunology and Transfusion Medicine, Haukeland University Hospital. This study was supported by the Norwegian Research Council, the Western Norway Regional Health Authority and the Norwegian Cancer Society.

Author Contributions

G.N., F.S., K.S.Å and L.H. designed the research; G.N., F.S., E.O., F.B., R.B., K.S.Å., S.O.D. and L.H. analyzed data; R.K., S.O.D., E.H. and M.B. generated the knockout mice; G.N., R.K., F.S., L.M., L.H., R.B., K.S.Å., E.O. and T.H.F.L. performed experiments; G.N., L.H., S.O.D. and F.S. wrote the paper and G.N., K.S.Å. and L.H. prepared the figures. All authors have read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-08975-y

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017